TY - JOUR
T1 - Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome
AU - Petri, Michelle
N1 - Funding Information:
Conflict-of-interest disclosure: M.P. is a consultant to and receives grant support from Exagen Inc.
Funding Information:
The Hopkins Lupus Cohort is funded by National Institutes of Health grant R01AR069572. Hopkins antiphospholipid research is also funded by the Gene D. Rubin Trust and the Sally Nyborg Foundation for Lupus Research.
Publisher Copyright:
© 2019 American Society of Hematology. All rights reserved.
PY - 2019/12/6
Y1 - 2019/12/6
N2 - Classification criteria for antiphospholipid syndrome have not been updated since the revised Sapporo classification criteria were published in 2006. These criteria have limitations in that they omit nonclassical manifestations (hematologic and neurologic), include anticardiolipin and anti-β2-glycoprotein I immunoglobulin (Ig)M isotypes, and do not separately consider primary (no autoimmune disease) or secondary (usually systemic lupus erythematosus) disease. Recent findings in antiphospholipid antibody include fluctuation of antiphospholipid antibodies, recognition that IgA isotypes do confer risk, identification of the role of complementopathy in catastrophic antiphospholipid syndrome, and elucidation of the role of thrombosis risk equations.
AB - Classification criteria for antiphospholipid syndrome have not been updated since the revised Sapporo classification criteria were published in 2006. These criteria have limitations in that they omit nonclassical manifestations (hematologic and neurologic), include anticardiolipin and anti-β2-glycoprotein I immunoglobulin (Ig)M isotypes, and do not separately consider primary (no autoimmune disease) or secondary (usually systemic lupus erythematosus) disease. Recent findings in antiphospholipid antibody include fluctuation of antiphospholipid antibodies, recognition that IgA isotypes do confer risk, identification of the role of complementopathy in catastrophic antiphospholipid syndrome, and elucidation of the role of thrombosis risk equations.
UR - http://www.scopus.com/inward/record.url?scp=85076251991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076251991&partnerID=8YFLogxK
U2 - 10.1182/hematology.2019000046
DO - 10.1182/hematology.2019000046
M3 - Article
C2 - 31808834
AN - SCOPUS:85076251991
SN - 1520-4391
VL - 2019
SP - 415
EP - 420
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -